|
|
|
| The influence of dydrogesterone combined with progynova on levels of endometrium TNF-α, VEGF, TGF-β of women with intrauterine adhesions after operation and its clinical efficacy |
| Hangzhou Obstetrics and Gynecology Hospital, Zhejiang Province, 310008 |
|
|
|
|
Abstract To explore the influence of dydrogesterone combined with progynova on levels of endometrium TNF-α, VEGF, TGF-β of women with intrauterine adhesions after operation, and to study the clinical efficacy of dydrogesterone combined with progynova. Methods: 156 women with moderate intrauterine adhesions were randomly divided into control group (n=78) and observation group (n=78) from February 2015 to May 2017. The women after operation in control group were treated by progynova, and the women in observation group were treated by dydrogesterone combined with progynova. The changes of tumor necrosis factor-α (TNF-α), vascular endothelial growth factor (VEGF) and transforming growth factor-β (TGF-β) in the endometrium of women were compared between the two groups, and the clinical efficacy and adverse reactions rate of women in both groups were observed. Results: Before treatment, there was no significant difference in the levels of TNF-α, VEGF and TGF-β of women between the two groups (P>0.05). After treatment, the levels of TNF-α, VEGF and TGF-βof women in the two groups were significantly lower than those before treatment (P<0.05), and the levels of TNF-α, VEGF and TGF-βof women in observation group were significantly lower than those of women in the control group (P<0.05).The rates of menstrual improvement and pregnancy of women in observation group were significant higher than those of women in control group, but the recurrence rate of intrauterine adhesions was significant lower than that of women in control group. There was no significant different in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Dydrogesterone combined with progynova can effectively decrease the expression of endometrium TNF-α, VEGF and TGF-β of women, which can improve the clinical efficacy，and do not increase the adverse reactions of women with intrauterine adhesions after operation.
|
|
|
|
|
|
|
|
|
